Transactions in connection with share buy-back program
Company announcement no.8 - 23
14 March 2023
Transactions in connection with share buy-back program
On 8 March 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 6 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.
The purposes of the share buy-back program are to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept, cover obligations arising under share-based incentive programs, and potentially for other purposes such as payment in relation to potential M&A transactions.
Under the share buy-back program NTG will purchase its own shares for an aggregate maximum amount of DKK 75,000,000, up to 250,000 shares (nominally DKK 5,000,000), corresponding to 1.10% of the current share capital of NTG.
The share buy-back program will run from 9 March 2023 to 5 May 2023 at the latest, both days inclusive.
The following transactions have been made under the share buy-back program:
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| 09 March 2023 | 6,000 | 350.7 | 2,103,910 |
| 10 March 2023 | 7,500 | 355.8 | 2,668,181 |
| 13 March 2023 | 8,000 | 349.0 | 2,792,154 |
| Accumulated under the program | 21,500 | 7,564,244 |
With the transactions stated above, NTG owns a total of 899,362 treasury shares, corresponding to 3.97% of the current share capital of NTG.
Details of each transaction are included as appendix.
Additional information
For additional information, please contact:
Investor relations: Christian D. Jakobsen, Group CFO | +45 42 12 80 99 ir@ntg.com |
| Press: Camilla Marcher Lydom, Investor Relations & Corporate Communication Manager | +45 42 12 80 90 press@ntg.com |
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sodexo and Harris Interactive reveal the results of the first international sustainable food barometer11.12.2023 08:03:00 CET | Press release
Issy-les-Moulineaux, France - December 11th, 2023 An action-oriented barometer: identifying and activating the change levers towards more sustainable diets. Sodexo reveals the results of the first international sustainable food barometer carried out in partnership with the research and opinion polls institute Harris Interactive. Conducted in 2023 among more than 5,000 people in Brazil, France, the United Kingdom and the United States, this exclusive study breaks down the disparities between people's representations of sustainable food and their associated behaviors for the first time. This action-oriented barometer aims to identify the concrete obstacles as well as the levers to induce changes in eating habits and accelerate the shift towards more sustainable diets. Sophie Bellon, Chairwoman of Sodexo’s Board of Directors & Chief Executive Officer: “Operating in 45 countries and serving 80 million consumers every day, Sodexo is a privileged observer of the changes in people's behaviors
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer11.12.2023 08:00:00 CET | Press release
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer Massimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical’s commercial and marketing operations to bring Versius to more hospitals around the worldMassimiliano joins CMR at a time of continued expansion as the second largest soft tissue surgical robotics company, with more than 140 Versius installations and more than 15,000 surgical procedures completedFollowing the recent $165 million financing round, CMR continues to pursue its expansion plans and new market regulatory approvals to bring Versius to more hospitals and patients around the world CAMBRIDGE, UK – Monday 11 December 2023, 07:00 (GMT). CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer. In his role, Massimiliano will oversee CMR’s commercial and marketing operations. Massimili
Azerion simplifies loan structures between Azerion and Principion11.12.2023 07:30:00 CET | Press release
Amsterdam, 11 December 2023 – Azerion Group N.V. ("Azerion") announces that it has today entered into an agreement with Principion Holding B.V. ("Principion") to simplify Azerion's loan structure by settling several loans outstanding between Azerion and Principion (the "Loan Settlement"). The objectives of the Loan Settlement are to simplify Azerion’s capital structure by setting off mutually outstanding unsecured liabilities, whilst at the same time providing Azerion with security against remaining balances. The Loan Settlement also provides Azerion the ability to use any ordinary shares in the capital of Azerion (the "Shares") to be acquired through the Loan Settlement mechanism for value creating purposes for all shareholders without the issuance of new Shares. The Loan Settlement has been approved by Azerion's management board and supervisory board. As at the date of this press release, the aggregate amount due and outstanding under the loans provided by (i) Principion to Azerion i
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®11.12.2023 07:30:00 CET | Press release
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced data from a real-world case series evaluating treatment of three complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023. Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%. There were no imp
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering